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Abstract
Background: Atrial fibrillation (AF) is the leading cause of stroke. The European Society of Cardiol-
ogy (ESC) advises opportunistic AF screening among patients aged ≥ 65 years. Considering this, the 
aim herein, was compare the feasibility of two different systems of smartphone-based electrocardiogram 
(ECG) recordings to identify AF among those without a previous arrhythmia history. 
Methods: Prospective AF screening was conducted at six pharmacies using Kardia Mobile and 
Hartmann Veroval 2 in 1. A single-lead ECG was acquired by the placement of fingers on the pads.  
A cardiologist evaluated findings from both devices.
Results: Atrial fibrillation was identified in 3.60% and previously unknown AF was detected in 1.92% 
of the study participants. Sensitivity and specificity of the Kardia application in detecting AF were 
66.7% (95% confidence interval [CI] 38.4–88.2%) and 98.5% (95% CI 96.7–99.5%), and for Veroval 
10.0% (95% CI 0.23–44.5%) and 94.96% (95% CI 92.15–96.98%), accordingly. Inter-rater agreement 
was k = 0.088 (95% CI 1.59–16.1%).
Conclusions: Mobile devices can detect AF, but each finding must be verified by a professional. The 
Kardia application appeared to be more user-friendly than Veroval. Cardiovascular screening using 
mobile devices is feasible at pharmacies. Hence it might be considered for routine use. (Cardiol J)
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Atrial fibrillation (AF) affects up to 34 million 
people worldwide [1, 2]. It is the most common 
cardiac arrhythmia with a prevalence of 1.5–2.0% in 
the general population. AF incidence has increased 
to almost 6% for those above 65 and 8.8% for those 
more than 80 years old [3–5]. AF is also the leading 
cause of stroke [1]. In many cases AF is asympto-
matic and in 25% of patients, it is diagnosed after 
a thromboembolic event [1, 6, 7]. Thus, it contrib-
utes to the significant economic and public health 
burden, with annual costs accounting for more than 
6.5 billion dollars in the United States [5, 6, 8–10].
Because the world’s population is aging quick-
ly [11, 12], the prevalence of AF is expected to 
double by 2060 [3]. One of the main challenges for 
healthcare is identifying AF as early as possible 
before a thromboembolic event occurs. There is 
a lot of data showing that adequate anticoagulation 
treatment reduces thromboembolic complications 
[3, 13]. The European Society of Cardiology (ESC) 
advises opportunistic AF screening in combination 
with the CHA2DS2-VASc score (Score for Atrial 
Fibrillation Stroke Risk [Congestive heart failure, 
Hypertension, Age ≥ 75, Diabetes mellitus, Stroke, 
Vascular disease, Age 65–74, Sex]) among patients 
aged ≥ 65 years [14, 15]. Although it is still not 
routinely performed [16, 17], new technologies 
such as mobile electrocardiogram (ECG) devices 
may facilitate the implementation of common AF 
screening [16, 18]. These technologies can detect 
AF [16, 17, 19, 20] and are both convenient and 
inexpensive [11, 21]. In their studies, Lowres et al. 
[19] and Zaprutko et al. [17] confirmed the feasibility 
of AF detection using mobile ECG in public places 
(e.g., pharmacies). They identified an incidence of 
AF in 1.5% and 1.33% of subjects without previ-
ous history of arrhythmia in Australia and Poland, 
respectively [17, 19]. Besides, Lowres et al. [19, 
20] reported Kardia Mobile to be cost-effective in 
screening patients for AF at pharmacies.
The objective of the present prospective study 
was to compare the feasibility of two different systems 
in identifying AF among those without a previous 
arrhythmia history. For that purpose, two different 
technologies were evaluated; Kardia Mobile with a 
dedicated smartphone application (app) and Hartmann 
Veroval 2 in 1 – ECG and Blood Pressure Monitor.
Methods
Atrial fibrillation screening was carried out 
between December 2018 and February 2020 at 
6 pharmacies located in different regions of Poland. 
The study was approved by the Bioethics Commit-
tee of Poznan University of Medical Sciences and 
by the pharmacy owners who agreed to conduct 
the research.
Pharmacists, cardiologists, and students from 
the Student Scientific Society of Pharmacoeconom-
ics and Social Pharmacy made up the research 
team. Students and non-physician researchers took 
part in a course on the basics of the used devices, 
thromboembolic risk assessment (the CHA2DS2- 
-VASc score), and ECG basics.
The Kardia Mobile with a Kardia app (iOS/An-
droid) is the Food and Drug Administration (FDA) 
approved device for recording, storing, and transfer 
of single-channel lead ECGs [16, 19]. 
A single-lead ECG from Kardia Mobile was 
acquired by placing fingers of both hands on the 
device pads for 30 s. The ECG’s electrical signals 
were modified to an ultrasonic frequency modula-
tion sound signal and then transmitted to a smart-
phone with the installed Kardia app [6]. The pro-
gram demodulated the signal to a digital ECG trace 
(300 samples/s, 16-bit resolution), displayed it in real- 
-time on the smartphone screen, and then transmit-
ted and stored it on a password-protected server [22].
Veroval is dedicated to blood pressure meas-
urement and for mobile ECG recording and con-
forms to European regulations based on the Euro-
pean Medical Device Directive 93/42/EEC. It bears 
the Conformité Européenne mark [23].
In this system, an ECG recording is acquired 
by placing a finger from the right hand on the upper 
electrode and one finger from the left hand on the 
lower electrode of the device. Veroval switches on 
automatically when the two fingers are placed on 
the electrodes. If the “ECG” notification appears 
on display, the device starts to record an ECG for 
30-s. When the recording is complete, the final 
ECG finding appears on display but the tracing 
is not visible. To over-read Veroval’s recordings, 
tracings are transferred via Bluetooth to software 
(Veroval medi.connect) on the user’s computer.
Kardia provided 7 and Veroval 8 possible find-
ings presented in Table 1 [22–25].
Inclusion criteria
Each patient visiting a pharmacy who looked to 
be 65 or more was asked to join the study. Younger 
patients or those with the previous history of AF 
were excluded from the study. A written informed 
consent with the patient’s phone number and 
CHA2DS2-VASc score was collected. Finally, an 




Each time, an ECG with the Kardia app was 
recorded first, followed by Veroval. ECG recordings 
from Kardia were saved as PDF files and password 
protected. For Veroval, the recordings were saved 
by the device (up to 64 measurements) and subse-
quently transferred via Bluetooth directly to the 
dedicated software. 
Stored ECG recordings were analyzed by car-
diologists (after logging in). One of the cardiologists 
analyzed the recordings and gave a diagnosis of 
“AF”, “non-AF,” or “non-interpretable”. If artifacts 
were present on the ECG recording or there was 
no ECG tracing despite the ECG finding presented 
on Veroval’s display, the recording was evaluated as 
“non-interpretable”. If the cardiologist had doubts 
about the diagnosis a second cardiologist was con-
sulted with the tracing to provide a final diagnosis.
If the cardiologist diagnosed AF, the patient 
was contacted by phone and advised to contact 
their general practitioner for a further evaluation. 
All of the patients were presented with an option 
to get their ECG tracing by e-mail or to pick up a 
printout at the pharmacy where it had been carried 
out (Suppl. Figs. 1–3).
Statistical analysis
A comparison of an AF diagnosis made by 
the analyzed application and the cardiologist was 
performed using the Fisher exact test. The sensi-
tivity and specificity, and predictive powers were 
calculated for the Kardia app, and Veroval took 
the cardiologist’s diagnosis as the gold standard. 
The Bland-Altman plot was used to describe the 
agreement between heart rates recorded by the ap-
plications. The difference in mean heart rate (HR) 
Table 1. Possible Kardia and Veroval findings.
Kardia possible findings Veroval possible findings
ECG finding Description ECG finding Description
POSSIBLE AF AF was detected based on of P-wave 
absence and R-R interval irregularity
OK Normal ECG recording
NORMAL The HR was regular and  
between 50 and 100 bpm, with  
shape, timing, and duration of every 
beat considered normal
FAST HR was higher than 100 bpm
UNCLASSIFIED The quality of tracing was good but  
the Kardia application could not  
differentiate between “possible AF”, 
and “normal” recordings (e.g., irregular 
rhythm due to premature complexes)
SLOW HR was lower than 55 bpm
UNREADABLE Resulted from poor ECG quality  
(e.g., due to sound or electrical  
interference)
PAUSE One or more brakes in the heart  
cycles that were longer than 2 s
TACHYCARDIA Regular HR faster than  
100 bpm
RHYTHM During the ECG recording supra- 
ventricular arrhythmia was detected  
(AF, atrial flutter, pathological  
sinus arrhythmia, paroxysmal atrial 
tachycardia, or supraventricular  
extrasystole)
BRADYCARDIA Regular HR was less than  
50 bpm
WAVE A changed ECG wave shape occurred 
(e.g., ventricular arrhythmias)
NO ANALYSIS There was no finding presented  




Indicated arrhythmia with changed 
wave shape (including singular  
ventricular extrasystole, bigeminy, 
trigemini, series of ventricular  
extrasystole, multifocal ventricular  
extrasystole, and ventricular  
tachycardia
ERROR Occurs e.g., if there was insufficient 
skin contact to the upper and  
lower electrodes
AF — atrial fibrillation; ECG — electrocardiogram; HR — heart rate
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values was tested by using the paired t-Student 
test. Additionally, the kappa coefficient was calcu-
lated to assess the agreement in the diagnosis of 
AF between the analyzed applications (inter-rater 
agreement).
Statistical analysis was performed using 
TIBCO Software Inc. (2017) and Statistica (data 
analysis software system), version 13. All tests 
were considered significant for p < 0.05.
Results
Out of 878 potential participants asked to join 
the study, 230 refused, and 115 were younger than 
65. Moreover, 94 patients were excluded due to 
their previous arrhythmia diagnoses, inability to 
fulfil the CHA2DS2-VASc protocol, or refusal to 
be subjected to a second (Veroval) ECG record-
ing. In addition, 22 patients were excluded from 
further analysis because they could not operate 
the device, e.g., due to shaking hands. Finally, 417 
patients were included in the study, and the study 
group structure is presented in Table 2. In addition, 
a distribution of the findings from the Kardia app 
and Veroval and cardiologists’ diagnoses is pre-
sented in Tables 3 and 4.
After the over-read of each recording (Kardia 
first followed by tracings from Veroval), AF was 
identified in 15 (3.60%) patients. However, the 
cardiologist’s interview revealed 7 (1.68%) patients 
admitted to the AF history. Hence, the study identi-
fied 8 (1.92%) patients with newly diagnosed AF. 
Importantly, due to the different quality of tracings, 
the Kardia app allowed us to detect 15 AF cases, 
whereas Veroval revealed 10. Inter-rater agree-
ment (kappa coefficient) between the devices was 
k = 0.088 (95% confidence interval [CI] 1.59–16.1%).
Sensitivity and specificity of the Kardia app in 
detecting AF were 66.7% (95% CI 38.4–88.2%) and 
98.5% (95% CI 96.7–99.5%), respectively. Positive 
predictive value (PPV) and negative predictive 
value (NPV) were 62.5% (95% CI 35.4–84.8%) and 
98.7% (95% CI 97.1–99.6%), respectively.
For Veroval the sensitivity and specificity of 
detecting AF were 10.0% (95% CI 0.23–44.5%) 
and 94.96% (95% CI 92.15–96.98%), accordingly. 
PPV and NPV were 5.23% (95% CI 0.12–26.03%) 
and 97.41% (95% CI 95.15–98.81%), respectively. 
Atrial fibrillation diagnosed by a cardiologist 
was frequently classified by Veroval as ventricular 
arrhythmia (simultaneous “rhythm” and “wave” 
finding). It resulted from the presence of iso-
electric line artifacts (also unknown), which the 









































































































































































































































































































































































































































































Table 3. Findings from Kardia application (n = 417) and diagnoses after the cardiologist’s over-read.
Kardia application findings After cardiologists over-read
Kardia finding Number of findings Diagnosis Number of findings










































AF — atrial fibrillation
Table 4. Findings from Veroval (n = 417) and diagnoses after the cardiologist’s over-read.
Veroval findings After cardiologists over-read
Veroval finding Number of findings Diagnosis Number of findings
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AF — atrial fibrillation
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Figure 1. The agreement between heart rates recorded by Kardia application and Veroval; HR — heart rate.
Bland-Altman HR Kardia vs. HR Hartmann
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considering “rhythm” and simultaneous “rhythm” 
and “wave” findings collectively and as a warning 
of supraventricular or ventricular arrhythmias, the 
sensitivity and specificity in detecting AF were 
90.0% (95% CI 55.52–99.75%) and 74.79% (95% 
CI 69.93–79.18%), respectively. The PPV and NPV 
were 9.09% (95% CI 4.25–16.55%) and 99.63% 
(95% CI 97.94–99.99%) respectively.
The mean heart rate for the Kardia app was 
78.30 ± 14.00; median 77 and for Veroval it was 
83.40 ± 21.53; median 79 (p < 0.001). The dis-
tribution of heart rate results is presented on the 
Bland-Altmann plot (Fig. 1).
Discussion
The most important result of the present study 
was that AF was identified in 3.60% of patients. 
Previously unknown AF was detected in 1.92% of 
the study participants. The Kardia app achieved 
this with an acceptable level of sensitivity and 
high specificity. For Veroval, the sensitivity was 
low, but specificity was high. According to the 
McHugh [26] study about inter-rater reliability, 
the k coefficient between the used devices was 
very low (k = 0.088).
Current results of new AF detection are in line 
with other studies. For example, using the Kardia 
app, Zaprutko et al. [17] found previously unknown 
AF in 1.33% of patients. In turn, Lowres et al. [19], 
and Halcox et al. [27] revealed new AF in 1.5% and 
1.84% of individuals, respectively. In the review 
provided by Ramkumar et al. [28], the average AF 
detection rate using portable ECG monitoring was 
1.7% (95% CI 1.4–2.1%).
In the present study, the sensitivity of the 
Kardia app was 66.77%. Alternatively, Zaprutko et 
al. [17] and Koshy et al. [29] revealed a sensitiv-
ity of 100%. Lau et al. [22] reported a sensitivity 
of 98%. A sensitivity of (71.4%) was presented 
by Chan et al. [16], this was close to the present 
result, but Desteghe et al. [30] reported sensitiv-
ity of the Kardia app at 36.8%. Thus, specificity 
was high in the current study and was in line with 
results revealed by Zaprutko et al. (98.7%), Lau et 
al. (97.0%), and William et al. (94.1%) [17, 22, 31].
The Kardia app’s PPV (62.5%) was lower than 
the result revealed, e.g., by Selder et al. (80%) [32]. 
PPV for Veroval (5.23%) was very low, and it was 
probably the effect of common artifacts in ECG 
tracings. Low PPV might be a drawback of port-
able ECG devices because they rely on a patient’s 
ability to perform the test accurately. The device 
might interpret any noise during an ECG recording 
as arrhythmia. These devices provide a finding, not 
a diagnosis, and all those true and false-positive 
tests should be re-evaluated by professionals [16]. 
Contrary to PPV, both the Kardia app and Veroval 
achieved a very high level of NPV (~99%). Chan 
et al. [16], screening tests should have both high 




During the last decade, there has been sig-
nificant development of mobile health applications, 
with approximately 3.7 billion downloaded globally 
between 2013 and 2017. These included many 
for detecting AF. Despite this, only a few of the 
apps have undergone a formal assessment [33]. 
Although we used approved devices, a very low 
inter-rater agreement (k = 0.088) between them 
was revealed. Contrary to this finding, Desteghe 
et al. [30] revealed no difference in the agree-
ment between the Kardia app and MyDiagnostick 
(a handheld ECG device). It may result from dif-
ferences in the methodology of these studies and 
automated algorithms used by the producers of 
such devices. Besides, Mant et al. [34] noticed that 
differences in diagnoses were possible when the 
interpretation was made by dedicated software or 
by different operators.
There was also a difference in heart rate meas-
urements between devices (Table 1). Veroval was 
used as a second device in each case, so the study 
participants should have been calmer. However, 
Veroval provided higher heart rate results. Consid-
ering findings revealed by Coppetti et al. [35], this 
is not surprising. They noticed that in smartphone 
applications for heart rate measurement, a differ-
ence of over 20 bpm occurred in more than 20% 
of all cases. Observed differences in bpm may also 
result from imperfections of the equipment used. 
For instance, Koshy et al. [36] found that smart-
watches demonstrated strong agreement for heart 
rate estimation in sinus rhythm, but the value was 
surprisingly underestimated in AF patients.
In the current study, the CHA2DS2-VASc score 
was lower in the group of non-AF patients (3.21 ± 
± 1.29) compared to those with newly identified AF 
(3.37 ± 1.51). Although it is in line with other stud-
ies, the difference obtained in the present study 
was lower than that revealed by Lowres et al. [19] 
(3.2 ± 1.1 for non-AF participants and 3.7 ± 1.1 
for those with newly identified AF) and by Yan et 
al. [3] (3.1 ± 1.9 for non-AF participants and 4.5 ± 
± 2.0 for those with present AF). Nevertheless, 
the presented results confirm that all AF patients 
are potential candidates for oral anticoagulants due 
to high stroke risk [19].
After a cardiologist assessment, there were 16 
(3.84%) non-interpretable Kardia app findings and 
53 (12.71%) such notifications from Veroval. The 
number of non-interpretable tracings may result 
from the fact that using the equipment for the first 
time could have been stressful for older people. 
Some issues may also have occurred  due to the 
evaluation of ECG quality by non-professionals 
[30, 37]. Moreover, tracings from handheld devices 
often have an unstable baseline and noise [30]. 
Importantly, for Veroval, it was impossible to 
view the recording on display (only findings were 
presented) and thus, an evaluation of the tracing 
quality. Unfortunately, it was quite common (n = 45; 
10.79%) that there was no ECG tracing after trans-
ferring an ECG recording to a computer, but the 
device provided a finding during the test.
The number of non-interpretable recordings 
from Veroval and those without tracings recorded 
might be the main reason for less (10 compared to 
15 from the Kardia app) AF cases diagnosed after 
a cardiologist’s evaluation. It could also partially 
explain the low k between devices. Besides, the 
number of Veroval’s tracings of poor quality may 
partly result from the chosen recording method. 
For Veroval, the first-choice option is the “right in-
dex finger-chest”, and the measurement stability is 
higher for this method. Despite this, the “left hand-
right hand” method was chosen, which is more 
comfortable [23], and ensured that the measure-
ment method by both devices was similar. Secondly, 
more patients were expected to refuse taking part 
if the recording would require partial undressing. 
However, electrodes pressed too firmly onto the 
skin, and the resulting muscle tension could lead 
to imprecisely measured values [23]. 
Ramkumar et al. [28] pointed out that the 
screening tool should also be affordable and cost-ef-
fective. Both devices might be considered inexpen-
sive and enable numerous recording repetitions. 
The official price of Kardia Mobile is US$ 89 (June 
2020). External entities distribute Veroval; thus, 
the price might vary and is usually between US$ 
120 and US$ 145 in Poland. Notably, several authors 
evaluated handheld ECG devices as cost-effective 
[14, 19, 30, 38]. For the Kardia app, Lowres et al. 
[19, 20] revealed an incremental cost-effectiveness 
ratio of €3142 per gained quality-adjusted life years 
(QALY). In turn, Jacobs et al. [4] showed that AF 
screening with a handheld mobile device provided 
an additional 0.27 QALYs with cost savings of EUR 
764 per patient. 
Despite possible advantages and drawbacks of 
mobile health technologies, the use of new tech-
nologies in AF screening may significantly impact 
the future of healthcare [39]. It could also support 
traditional healthcare delivery [33], especially 
during a pandemic. Furthermore, high specificity, 
high NPV, and affordability of the used devices may 
lead to the opportunistic AF screening becoming 
common and feasible, e.g., at pharmacies. Besides, 
formally evaluated apps and devices demonstrate 
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improvements in patient knowledge of AF and oral 
anticoagulants. Hence, it contributes to medication 
adherence, a better quality of life, and more effec-
tive treatment [33].
Limitations of the study
The study sample could have been larger. 
However, the present study was suddenly stopped 
due to the COVID-19 pandemic. The subsequent 
lockdowns of the country and severely limited 
physical contact between people after the gradual 
opening of the national economy were significant 
obstacles for the study. Besides, the study was not 
advertised anywhere to avoid pharmacy advertis-
ing, which is unlawful in Poland [40, 41]. It would be 
worthwhile to conduct the screening with Veroval 
using the first-choice option from Veroval’s manual 
to have a possibly better quality of recordings. Op-
portunistic and one-time ECG screening may miss 
patients with paroxysmal AF.
Implications for future research
Although both devices provide similar useful-
ness for ECG recordings, there are differences 
between them. In our opinion, the Kardia app is 
more user-friendly, i.e., the Veroval is more chal-
lenging to use. For the Kardia app, the transfer of 
recordings is more convenient, and the  quality of 
recordings is better. Although smartphones are 
common right now [42, 43], Veroval, contrary to 
the Kardia app, does not require a smartphone 
to provide an ECG recording. However, tracing 
provided by Veroval is visible after transfer to the 
computer’s software. Therefore, it does not allow 
one to evaluate if tracing is of good quality in an 
instant. Veroval is simultaneously a blood pressure 
monitor, which makes the device multifunctional. 
The low level of Veroval’s sensitivity in detecting 
AF should be relevant motivation for the producer 
to improve the algorithms used for supraventricu-
lar arrhythmia/AF detection.
Conclusions
Atrial fibrillation was identified in 3.60% of 
patients and in 1.92% of patients (≥ 65 years old) 
with a previously undiagnosed AF. Mobile devices 
are capable of detecting AF but with different levels 
of sensitivity and specificity. The very low inter-
rater agreement between devices confirmed that 
each finding must be verified by a professional. The 
Kardia app appeared to be more user-friendly than 
Veroval. Due to a better quality of ECG tracings, 
cardiologists confirmed more new AF cases based 
on the tracings from the Kardia app than solely 
based on Veroval. Cardiovascular screening using 
mobile devices is feasible at pharmacies; hence it 
might be considered for routine use.
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